A 64-Year-Old Man Hospitalized for COVID-19 Pneumonia and Treated with Tocilizumab Who Developed Chronic Cavitary Pulmonary Aspergillosis

Adetiloye, Adebola; Alladin, Farhana; Alaameri, Rasha; Valencia-Manrique, Julio C.; Badero, Olurotimi J.; Poor, A.

doi:10.12659/ajcr.938359

Cited by 2 publications

(1 citation statement)

References 32 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most superinfections found were ventilator-associated pneumonia caused by Staphylococcus aureus in about 50% of cases. In the literature, there have been reports of candidemia and invasive pulmonary aspergillosis occurring in patients who were treated with TZB ( 43 , 44 ). In our study cohort, bacteriemia was found in 20 (16.53%) patients, with Acinetobacter spp.…”

Section: Discussionmentioning

confidence: 99%

What did we learn about tocilizumab use against COVID-19? A single-center observational study from an intensive care unit in Serbia

Adzic-Vukicevic,

Markovic,

Reljic

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundSelection of effective and safe therapy for management of patients with coronavirus disease is challenging. Tocilizumab (TZB) has emerged as a potential treatment option for COVID-19. Several aspects regarding Tocilizumab treatment remain uncertain, such as the optimal timing for its administration and the safety profile, including the potential risk of infections. The aim of the study is to present the clinical characteristics of patients with COVID-19 following the application of Tocilizumab.MethodsThis is a retrospective analysis of 121 patients with severe forms of COVID-19 previously treated with Tocilizumab was conducted. All patients were admitted to intensive care units (ICUs).ResultsOf 121 patients, the majority were men 72 (59.5%) with a median age at presentation of 65 ± 13 years. Only 9 (7.43%) patients were without comorbidities, while the other 112 (92.55%) had two or more comorbidities. Almost all of the 120 patients (99.2%) needed oxygen therapy, such as nasal cannulas in 110 (90.9%) patients, high flow nasal catheter (HFNC) in 4 (3.3%) patients, and continuous positive airway pressure (CPAP) in 5 (4.1%) patients while 1 patient was intubated at the time of hospital admission. The average time from Tocilizumab application to admission to the ICU was 3 days. During clinical deterioration, almost half 57 (47.1%) of the patients were intubated, and 52 (82.5%) of these intubated patients (p < 0.001) had lethal outcomes. The most significant predictors for a lethal outcome according to multivariate analysis were diabetes mellitus (p < 0.001) followed by a subsequent elevation in C-reactive protein levels (CRP; p < 0.002) and ferritin (p < 0.013) after Tocilizumab application. Bloodstream infections were found in 20 (16.5%) patients, most frequently with Gram-negative pathogens like Acinetobacter spp. as in 12 (18.6%) patients, Klebsiella spp. in 6 (8%) patients, and Pseudomonas spp. in 2 (3.2%) patients. Urine culture isolates were found in 9 (7.43%) patients, with Candida spp. being most frequently isolated in 7 (5.8%) patients, followed by Klebsiella spp. and Pseudomonas spp. in 1 patient each (0.8%). Significantly lower survival was seen in patients with proven infection.ConclusionThe benefit of tocilizumab was not found in our study. The high mortality rate among intubated patients after Tocilizumab use suggests appropriate patient selection and monitoring and emphasizes the risk of superinfections. Diabetes mellitus, increased levels of CRP, and ferritin were identified as the most significant predictors of poor outcomes in contrast to increased levels of IL-6.

show abstract

Section: Discussionmentioning

confidence: 99%